/
In this section, unless otherwise specified, references to we, our, us and our company refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) ( Gyre Pharmaceuticals ). Overview We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-mol…
Operating margin is thin at 9.85%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 10.2%, still solid. Margins contracted 5.4pp, which offsets some of the top-line progress.
ROIC dropped from 33.20% to 8.06%, capital efficiency is deteriorating. Negative free cash flow of -$180K. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$117M
▲ +10.2% YoY
Net Income (TTM)
-$4M
▼ -44.8% YoY
Op. Margin
-0.12%
▼ -5.4pp YoY
ROIC
-0.11%
▼ -25.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$3M
▲ +97.0% YoY
Op. Cash Flow (TTM)
$4M
▲ +127.7% YoY
Net Debt
-$49M
Net Cash Position
Cash & Equiv.
$50M
5Y CAGR: +41.0%
Continue Research